---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-029810"
form_type: "8-K"
ticker: "INBP"
cik: "0001016504"
company_name: "INTEGRATED BIOPHARMA INC"
filed_at: "2024-09-23T23:59:59+00:00"
generated_at: "2026-05-31T02:14:55.624307+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Integrated BioPharma Q4 net income $0.3M ($0.01/share); FY net income $112K vs loss $34K

## Summary
- Revenue Q4 $12.7M (-2.3% YoY); FY $50.3M (-0.7% YoY).
- Operating income improved to $402K Q4 and $251K FY, from $79K and $120K prior.
- Net income Q4 $268K ($0.01 diluted) vs $40K ($0.00); FY net income $112K ($0.00) vs net loss $34K.
- Two largest customers accounted for 90% of FY2024 revenue (89% prior year).
- Co-CEOs cite focus on core businesses and new prospects to diversify customer base.

## SEC filing metadata
- accession: 0001437749-24-029810
- form_type: 8-K
- ticker: INBP
- cik: 0001016504
- company_name: INTEGRATED BIOPHARMA INC
- filed_at: 2024-09-23T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1016504/000143774924029810/0001437749-24-029810-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1016504/000143774924029810/inbp20240917_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-029810
- JSON: https://secwatch.observer/filing/0001437749-24-029810.json
- Plain text: https://secwatch.observer/filing/0001437749-24-029810.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.